Related Experiment Video
Updated: Sep 20, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Long non-coding RNA NORAD suppresses erastin-induced ferroptosis in breast cancer by upregulating SLC7A11 via
Pengfei Shi1, Bo Hu1, Yongjun Liu1
1Department of Thyroid and Breast Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Background:
Ferroptosis, an iron-dependent cell death, has been widely reported to impede the progression of various malignancies, including breast cancer (BC). Previous evidence has indicated that high expression of non-coding RNA activated by DNA damage (NORAD) is correlated with poor prognosis in BC patients. Nonetheless, it is unclear whether NORAD plays a role in the ferroptosis of BC cells.
Methods:
BC cells were treated with the ferroptosis agonist erastin to induce ferroptosis. Western blotting and quantitative real-time polymerase chain reaction were employed to determine protein and RNA levels, respectively. The cell counting kit-8 assay was used to assess cell viability. Mitochondrial morphology, lipid peroxidation, and intracellular Fe 2+ , malondialdehyde, and glutathione levels were evaluated for ferroptosis. Chromatin immunoprecipitation, luciferase reporter, and RNA immunoprecipitation assays were conducted to explore the molecular mechanism of NORAD. A xenograft mouse model (BALB/c nude) was established to evaluate NORAD's effect on ferroptosis of BC in vivo .
Results:
NORAD displayed a high level in human BC tissues and cells. NORAD overexpression and silencing inhibited and facilitated erastin-induced ferroptosis of BC cells, respectively. NORAD upregulated NR3C1 expression via interaction with FUS, and NR3C1 could transcriptionally upregulate solute carrier family 7 member 11 (SLC7A11). Overexpressing SLC7A11 could reverse NORAD silencing-mediated promotion of ferroptosis. NORAD upregulation attenuated the antitumor activity of erastin in tumor-bearing mice.
Conclusions:
NORAD upregulates SLC7A11 via the FUS/NR3C1 axis, thereby suppressing erastin-induced ferroptosis of BC cells.
Insights
Non-coding RNA activated by DNA damage (NORAD) suppresses ferroptosis in breast cancer (BC) by upregulating SLC7A11. This finding reveals NORAD as a potential therapeutic target for BC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cell Death Research
Background:
- Ferroptosis, a form of iron-dependent cell death, is a known impediment to various cancers, including breast cancer (BC).
- High expression of non-coding RNA activated by DNA damage (NORAD) correlates with poor prognosis in BC patients.
- The specific role of NORAD in BC ferroptosis remains largely unexplored.
Purpose of the Study:
- To investigate the role of NORAD in regulating ferroptosis in breast cancer cells.
- To elucidate the molecular mechanism by which NORAD influences ferroptosis.
- To assess the in vivo effect of NORAD on breast cancer ferroptosis.
Main Methods:
- Breast cancer cells were treated with erastin to induce ferroptosis.
- Western blotting and qPCR assessed molecular levels; CCK-8 assays evaluated cell viability.
- Mechanisms were explored using ChIP, luciferase reporter, and RIP assays; in vivo studies utilized a xenograft mouse model.
Main Results:
- NORAD was highly expressed in human BC tissues and cells.
- NORAD overexpression inhibited erastin-induced ferroptosis, while silencing facilitated it.
- NORAD upregulated NR3C1 via FUS interaction, which in turn upregulated SLC7A11, reversing ferroptosis promotion by NORAD silencing.
Conclusions:
- NORAD suppresses erastin-induced ferroptosis in breast cancer cells.
- This suppression occurs through the FUS/NR3C1 axis, leading to the upregulation of SLC7A11.
- NORAD's role in ferroptosis suppression suggests it as a potential therapeutic target for breast cancer.
Related Concept Videos
lncRNA - Long Non-coding RNAs
MicroRNAs
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Experimental RNAi
The Nucleolus
Non-LTR Retrotransposons

